Circulating levels of soluble receptor for advanced glycation end products and ligands of the receptor for advanced glycation end products in patients with acute liver failure

Liver Transplantation

Volumn 21, Issue 6, 2015, Pages 847-854

  Basta, Giuseppina ^a   Del Turco, Serena ^a   Navarra, Teresa ^a   Lee, William M ^b  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT RECEPTOR; BINDING PROTEIN; HIGH MOBILITY GROUP PROTEIN; LIGAND; PARACETAMOL; ADVANCED GLYCATION END PRODUCT; AGER PROTEIN, HUMAN; BIOLOGICAL MARKER; CALGRANULIN C; HIGH MOBILITY GROUP B1 PROTEIN; HMGB1 PROTEIN, HUMAN; LYSINE; N(6)-CARBOXYMETHYLLYSINE; S100A12 PROTEIN, HUMAN;

ACUTE LIVER FAILURE; ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; ANALOGS AND DERIVATIVES; BLOOD; CASE CONTROL STUDY; CHEMICALLY INDUCED; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; YOUNG ADULT;

ACETAMINOPHEN; ADULT; ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; BIOMARKERS; CASE-CONTROL STUDIES; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HMGB1 PROTEIN; HUMANS; LIVER FAILURE, ACUTE; LYSINE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; S100A12 PROTEIN; YOUNG ADULT;

EID: 84930035644     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.24129     Document Type: Article

References (43)

1. Vaquero J, Blei AT,. Etiology and management of fulminant hepatic failure. Curr Gastroenterol Rep 2003; 5: 39-47.
2. Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, et al.,; for Acute Liver Failure Study Group. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005; 42: 1364-1372.
3. Lee WM,. Acetaminophen-related acute liver failure in the United States. Hepatol Res 2008; 38 (suppl 1): S3-S8.
4. Lee WM,. Acute liver failure in the United States. Semin Liver Dis 2003; 23: 217-226.
5. Squires RH Jr, Shneider BL, Bucuvalas J, Alonso E, Sokol RJ, Narkewicz MR, et al., Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr 2006; 148: 652-658.
6. Craig DG, Lee A, Hayes PC, Simpson KJ,. Review article: the current management of acute liver failure. Aliment Pharmacol Ther 2010; 31: 345-358.
7. Dhiman RK, Jain S, Maheshwari U, Bhalla A, Sharma N, Ahluwalia J, et al., Early indicators of prognosis in fulminant hepatic failure: an assessment of the Model for End-Stage Liver Disease (MELD) and King's College Hospital criteria. Liver Transpl 2007; 13: 814-821.
8. MacQuillan G,. Predicting outcome in acute liver failure: are we there yet? Liver Transpl 2007; 13: 1209-1211.
9. Harbrecht BG,. Predicting outcome in patients with acute liver failure: what works best? Crit Care Med 2012; 40: 1666-1667.
10. Blei AT,. Selection for acute liver failure: have we got it right? Liver Transpl 2005; 11 (suppl 2): S30-S34.
11. Panis Y, McMullan DM, Emond JC,. Progressive necrosis after hepatectomy and the pathophysiology of liver failure after massive resection. Surgery 1997; 121: 142-149.
12. Zeng S, Feirt N, Goldstein M, Guarrera J, Ippagunta N, Ekong U, et al., Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice. Hepatology 2004; 39: 422-432.
13. Sternberg DI, Gowda R, Mehra D, Qu W, Weinberg A, Twaddell W, et al., Blockade of receptor for advanced glycation end product attenuates pulmonary reperfusion injury in mice. J Thorac Cardiovasc Surg 2008; 136: 1576-1585.
14. Ekong U, Zeng S, Dun H, Feirt N, Guo J, Ippagunta N, et al., Blockade of the receptor for advanced glycation end products attenuates acetaminophen-induced hepatotoxicity in mice. J Gastroenterol Hepatol 2006; 21: 682-688.
15. Basta G, Navarra T, De Simone P, Del Turco S, Gastaldelli A, Filipponi F,. What is the role of the receptor for advanced glycation end products-ligand axis in liver injury? Liver Transpl 2011; 17: 633-640.
16. Zhang L, Bukulin M, Kojro E, Roth A, Metz VV, Fahrenholz F, et al., Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem 2008; 283: 35507-35516.
17. Basta G,. Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications. Atherosclerosis 2008; 196: 9-21.
18. Kalousová M, Hodková M, Kazderová M, Fialová J, Tesar V, Dusilová-Sulková S, Zima T,. Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis 2006; 47: 406-411.
19. Ostapowicz G, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SH, et al.,; for U.S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137: 947-954.
20. Polson J, Lee WM,; for American Association for the Study of Liver Disease. AASLD position paper: the management of acute liver failure. Hepatology 2005; 41: 1179-1197.
21. Stravitz RT, Kramer AH, Davern T, Shaikh AO, Caldwell SH, Mehta RL, et al.,; for Acute Liver Failure Study Group. Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med 2007; 35: 2498-2508.
22. Wiesner RH, McDiarmid SV, Kamath PS, Edwards EB, Malinchoc M, Kremers WK, et al., MELD and PELD: application of survival models to liver allocation. Liver Transpl 2001; 7: 567-580.
23. Hadem J, Stiefel P, Bahr MJ, Tillmann HL, Rifai K, Klempnauer J, et al., Prognostic implications of lactate, bilirubin, and etiology in German patients with acute liver failure. Clin Gastroenterol Hepatol 2008; 6: 339-345.
24. Miniati M, Monti S, Basta G, Cocci F, Fornai E, Bottai M,. Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study. Respir Res 2011; 12: 37.
25. Basta G, Berti S, Cocci F, Lazzerini G, Parri S, Papa A, et al., Plasma N-epsilon-(carboxymethyl)lysine levels are associated with the extent of vessel injury after coronary arterial stenting. Coron Artery Dis 2008; 19: 299-305.
26. Basta G, Sironi AM, Lazzerini G, Del Turco S, Buzzigoli E, Casolaro A, et al., Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab 2006; 91: 4628-4634.
27. Bechmann LP, Jochum C, Kocabayoglu P, Sowa JP, Kassalik M, Gieseler RK, et al., Cytokeratin 18-based modification of the MELD score improves prediction of spontaneous survival after acute liver injury. J Hepatol 2010; 53: 639-647.
28. Cohen MJ, Carles M, Brohi K, Calfee CS, Rahn P, Call MS, et al., Early release of soluble receptor for advanced glycation endproducts after severe trauma in humans. J Trauma 2010; 68: 1273-1278.
29. Bopp C, Hofer S, Weitz J, Bierhaus A, Nawroth PP, Martin E, et al., sRAGE is elevated in septic patients and associated with patients outcome. J Surg Res 2008; 147: 79-83.
30. Weigand MA, Schmidt H, Pourmahmoud M, Zhao Q, Martin E, Bardenheuer HJ,. Circulating intercellular adhesion molecule-1 as an early predictor of hepatic failure in patients with septic shock. Crit Care Med 1999; 27: 2656-2661.
31. Ohnishi A, Miyake Y, Matsushita H, Matsumoto K, Takaki A, Yasunaka T, et al., Serum levels of soluble adhesion molecules as prognostic factors for acute liver failure. Digestion 2012; 86: 122-128.
32. Navarra T, De Simone P, Del Turco S, Filipponi F, Basta G,. Involvement of the receptor for advanced glycation end products in liver transplantation. Ann Hepatol 2015; 14: 190-197.
33. Higuchi S, Yano A, Takai S, Tsuneyama K, Fukami T, Nakajima M, Yokoi T,. Metabolic activation and inflammation reactions involved in carbamazepine-induced liver injury. Toxicol Sci 2012; 130: 4-16.
34. Martin-Murphy BV, Holt MP, Ju C,. The role of damage associated molecular pattern molecules in acetaminophen-induced liver injury in mice. Toxicol Lett 2010; 192: 387-394.
35. Antoine DJ, Williams DP, Kipar A, Jenkins RE, Regan SL, Sathish JG, et al., High-mobility group box-1 protein and keratin-18, circulating serum proteins informative of acetaminophen-induced necrosis and apoptosis in vivo. Toxicol Sci 2009; 112: 521-531.
36. Tsung A, Sahai R, Tanaka H, Nakao A, Fink MP, Lotze MT, et al., The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 2005; 201: 1135-1143.
37. Watanabe T, Kubota S, Nagaya M, Ozaki S, Nagafuchi H, Akashi K, et al., The role of HMGB-1 on the development of necrosis during hepatic ischemia and hepatic ischemia/reperfusion injury in mice. J Surg Res 2005; 124: 59-66.
38. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al., HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248-251.
39. Craig DG, Lee P, Pryde EA, Masterton GS, Hayes PC, Simpson KJ,. Circulating apoptotic and necrotic cell death markers in patients with acute liver injury. Liver Int 2011; 31: 1127-1136.
40. Rouhiainen A, Tumova S, Valmu L, Kalkkinen N, Rauvala H,. Pivotal advance: analysis of proinflammatory activity of highly purified eukaryotic recombinant HMGB1 (amphoterin). J Leukoc Biol 2007; 81: 49-58.
41. Bianchi ME,. HMGB1 loves company. J Leukoc Biol 2009; 86: 573-576.
42. Achouiti A, Föll D, Vogl T, van Till JW, Laterre PF, Dugernier T, et al., S100A12 and soluble receptor for advanced glycation end products levels during human severe sepsis. Shock 2013; 40: 188-194.
43. Anderson MM, Requena JR, Crowley JR, Thorpe SR, Heinecke JW,. The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 1999; 104: 103-113.